• 1
    Spechler SJ. Epidemiology and natural history of gastro- oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 249.
  • 2
    McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux esophagitis: a 10 year follow up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 4816.
  • 3
    Bardhan KD. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy — a sideways glance. Yale J Biol Med 1996; 69: 21124.
  • 4
    Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International Gord Study Group. Eur J Gastroenterol Hepatol 1998; 10: 11924.
  • 5
    Chiba N, De Gara CJ, Wilkinson JM, Hunt RH. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112: 1798810.
  • 6
    Carling L, Axelsson CK, Forssell H, et al. Lansoprazole and omeprazole in the prevention of relapse of reflux esophagitis: a long-term comparative study. Aliment Pharmacol Ther 1998; 12: 98590.
  • 7
    Caro JJ, Salas M, Ward A. Healing and relapse rates in gastroesophageal reflux disease treated with the newer proton-pump inhibitors lansoprazole, rabeprazole, and pantoprazole compared with omeprazole, ranitidine, and placebo: evidence from randomized clinical trials. Clin Ther 2001; 23: 9981017.
  • 8
    Chiba N. Proton pump inhibitors in acute healing and maintenance of erosive or worse esophagitis: a systematic overview. Can J Gastroenterol 1997; 11(Suppl. B): 66B73B.
  • 9
    Talley NJ, Dent J, Brun J, et al. An evidence-based appraisal of reflux disease management — The Genval Workshop Report. Gut 1999; 44(Suppl. 2): S116.
  • 10
    Thomson AB, Chiba N, Armstrong D, Tougas G, Hunt RH. The Second Canadian Gastroesophageal Reflux Disease Consensus: moving forward to new concepts. Can J Gastroenterol 1998; 12: 5516.
  • 11
    DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 1999; 94: 143442.
    Direct Link:
  • 12
    Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 8617.
  • 13
    Röhss K, Nilsson-Claar C, Rydholm H, Nyman L. Esomeprazole 40 mg provides more effective acid control than lansoprazole 30 mg. Gastroenterology 2000; 118(Suppl. 2): A20(Abstract).
  • 14
    Wilder-Smith C, Röhss K, Lundin C, Rydholm H. Esomeprazole (E) 40 mg provides more effective acid control than pantoprazole (P) 40 mg. Gastroenterology 2000; 118(Suppl. 2): A22-3.
  • 15
    Wilder-Smith C, Röhss K, Claar-Nilsson C. Esomeprazole 40 mg provides more effective acid control than rabeprazole 20 mg. Gut 2000; 47: (Suppl. III): A51(Abstract).
  • 16
    Wilder-Smith C, Röhss K, Claar-Nilsson C. Esomeprazole 20 mg provides more effective acid control than lansoprazole 15 mg. Am J Gastroenterol 2001; 96(Suppl. 9): S44.
  • 17
    Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The esomeprazole study investigators. Aliment Pharmacol Ther 2000; 14: 124958.
  • 18
    Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in gerd patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 65665.
    Direct Link:
  • 19
    Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 57583.
    Direct Link:
  • 20
    Johnson DA, Benjamin SB, Vakil NB, et al. Esomeprazole once daily for 6 months is effective therapy for maintaining healed erosive esophagitis and for controlling gastroesophageal reflux disease symptoms: a randomized, double-blind, placebo-controlled study of efficacy and safety. Am J Gastroenterol 2001; 96: 2734.
    Direct Link:
  • 21
    Vakil NB, Shaker R, Johnson DA, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 92735.
  • 22
    National Institute for Clinical Excellence. Guidance on the Use of Proton Pump Inhibitors (PPI) in the Treatment of Dyspepsia. London: National Institute of Clinical Excellence, 2000: 113.
  • 23
    British National Formulary, 38th edn.London: British Medical Association and the Royal Pharmaceutical Society of Great Britain, 2002.
  • 24
    TAP Pharmaceuticals, IL, USA. Lansoprazole Prescribing Information. Available from
  • 25
    Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of esophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 17280.
  • 26
    Edwards SJ, Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. Aliment Pharmacol Ther 2001; 15: 172936.
  • 27
    Gough AL, Long RG, Cooper BT, Fosters CS, Garrett AD, Langworthy CH. Lansoprazole versus ranitidine in the maintenance treatment of reflux esophagitis. Aliment Pharmacol Ther 1996; 10: 52939.
  • 28
    Robinson M, Lanza F, Avner D, Haber M. Effective maintenance treatment of reflux esophagitis with low-dose lansoprazole. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996; 124: 85967.
  • 29
    Hatlebakk JG, Berstad A. Lansoprazole 15 and 30 mg daily in maintaining healing and symptom relief in patients with reflux oesophagitis. Aliment Pharmacol Ther 1997; 11: 36572.
  • 30
    Freston JW, Jackson RL, Huang B, Ballard ED. Lansoprazole for maintenance of remission of erosive esophagitis. Drugs 2002; 62: 117384.
  • 31
    Kahrilas PJ. Strategies for medical management of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 77591.
  • 32
    Venables TL, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 96573.
  • 33
    Klinkenberg-Knol EC, Festen HP, Jansen JB, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 1617.
  • 34
    Marks RD, Richter JE, Rizzo J, et al. Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 1994; 106: 90715.
  • 35
    Smith PM, Kerr GD, Cockel R, et al. A comparison of omeprazole and ranitidine in the prevention of recurrence of benign esophageal stricture. Gastroenterology 1994; 107: 13128.